Raymond James Financial
BBIO icon

Raymond James Financial’s BridgeBio Pharma BBIO Stock Holding History

Raymond James Financial’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.4M Sell
153,474
-158,485
-51% -$11.1M ﹤0.01% 2032
2026
Q1 		$22.3M Buy
311,959
+194,458
+165% +$14.1M 0.01% 1387
2025
Q4 		$8.99M Buy
117,501
+11,002
+10% +$722K ﹤0.01% 2058
2025
Q3 		$5.53M Buy
106,499
+24,404
+30% +$1.19M ﹤0.01% 2388
2025
Q2 		$3.54M Buy
82,095
+8,503
+12% +$309K ﹤0.01% 2620
2025
Q1 		$2.54M Buy
73,592
+56,961
+342% +$1.92M ﹤0.01% 2825
2024
Q4 		$456K Buy
+16,631
New +$430K ﹤0.01% 3967

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Raymond James Financial's BBIO Position: Q2 2026 in Review

Raymond James Financial reduced its BridgeBio Pharma (BBIO) stake by 51% in Q2 2026, selling an estimated $11.1M and leaving 153,474 shares worth $11.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2032.

Raymond James Financial first reported a position in BBIO in Q4 2024 and has held it in 7 quarters since. The position peaked at $22.3M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Raymond James Financial held 153,474 shares of BridgeBio Pharma worth $11.4M as of Q2 2026.
  • Raymond James Financial sold 158,485 BridgeBio Pharma shares in Q2 2026, an estimated $11.1M.
  • BridgeBio Pharma made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2032 holding.
  • Raymond James Financial first reported a position in BridgeBio Pharma in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's BridgeBio Pharma position peaked at $22.3M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.